774 studies found for:    Erlotinib
Show Display Options
Rank Status Study
1 Terminated Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Condition: Ependymoma
Intervention: Drug: Erlotinib
2 Terminated
Has Results
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Condition: Breast Cancer
Interventions: Drug: erlotinib hydrochloride;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy
3 Active, not recruiting Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Condition: Head And Neck Cancer
Intervention: Drug: Erlotinib
4 Terminated Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer;   Glioblastoma Multiforme
Interventions: Drug: Vorinostat;   Drug: Erlotinib;   Drug: Temozolomide
5 Completed Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Conditions: Cancer;   Pancreas
Intervention: Drug: Erlotinib
6 Completed Erlotinib in Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Erlotinib
7 Completed Erlotinib Versus Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Erlotinib;   Drug: Intravenous chemotherapy
8 Active, not recruiting Erlotinib in Combination With Cetuximab
Condition: Advanced Cancers
Interventions: Drug: Erlotinib;   Drug: Cetuximab
9 Active, not recruiting Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib;   Drug: Hydroxychloroquine
10 Recruiting Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Pralatrexate
11 Active, not recruiting Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Conditions: Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer
Intervention: Drug: Erlotinib + Rosuvastatin
12 Completed Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
13 Completed
Has Results
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pralatrexate Injection;   Drug: Erlotinib;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
14 Terminated
Has Results
Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma
Condition: Recurrent or Refractory Pediatric Ependymoma
Interventions: Drug: erlotinib;   Drug: etoposide
15 Completed Ph I Dasatinib + Erlotinib in Recurrent MG
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Erlotinib and Dasatinib
16 Completed
Has Results
Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Bevacizumab and Erlotinib
17 Active, not recruiting Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Erlotinib;   Drug: Erlotinib plus sulindac;   Drug: Placebo
18 Active, not recruiting Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Condition: Non-small Cell Lung Cancer
Intervention: Drug: erlotinib
19 Active, not recruiting EGFR Inhibition Using High Dose Administration of Erlotinib Weekly for Recurrent Malignant Gliomas With EGFR Variant III Mutation
Condition: Brain Cancer
Intervention: Drug: erlotinib
20 Withdrawn OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
Condition: Pancreatic Cancer, Metastatic
Interventions: Drug: Gemcitabine, Erlotinib, OSI-906;   Drug: Gemcitabine, Erlotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years